Correlation Engine 2.0
Clear Search sequence regions


  • humans (1)
  • injuries (1)
  • patients (1)
  • prostate (2)
  • urethra (2)
  • Sizes of these terms reflect their relevance to your search.

    To assess the correlation between postimplant dosimetric quantifiers and the genitourinary (GU) toxicity of low-dose rate brachytherapy for prostate cancer. The minimum urethral dose (UD10, 30, and 90) and the percent volume of the urethra receiving the prescription dose (V100, V150) were calculated from the postimplant dose-volume histograms of 182 patients. We then calculated various urethral biologically equivalent doses (uBEDs) using different values of the α/β ratio and tissue repair half-time (t1/2) and examined the correlations with GU toxicity. Common dosimetric quantifiers, such as UD90 (brachytherapy) + UD50 (external beam radiotherapy), showed no correlation with Grade ≥ 2 GU toxicity. There was a significant correlation between Grade ≥2 GU toxicity and uBED when the α/β value was 0.5 or 1 Gy and t1/2 was 0.5-2.5 h. An uBED (α/β = 1.0, t1/2 = 0.5) had the largest hazard ratio for GU toxicity, and it was also significantly correlated with Grade ≥ 2 GU toxicity according to multivariate analysis. We observed a significant correlation of uBED with GU toxicity when α/β was 0.5 or 1.0 Gy and t1/2 was 0.5-2.5 h. As the simple formula we used has not been verified in basic experiments, more data are needed to validate our results. Copyright © 2020 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

    Citation

    Toshio Gocho, Masakazu Hori, Yuuki Fukushima, Masanori Someya, Mio Kitagawa, Tomokazu Hasegawa, Takaaki Tsuchiya, Masato Hareyama, Masaru Takagi, Kohei Hashimoto, Naoya Masumori, Koh-Ichi Sakata. Evaluation of the urethral α/β ratio and tissue repair half-time for iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy. Brachytherapy. 2020 May - Jun;19(3):290-297

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 32249179

    View Full Text